Noxopharm Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Gisela Mautner

Algemeen directeur

AU$500.6k

Totale compensatie

Percentage CEO-salaris	94.3%
Dienstverband CEO	2.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	4.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Gisela Mautner's beloning veranderd ten opzichte van Noxopharm's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$501k	AU$472k	-AU$4m
Mar 31 2024	n/a	n/a	-AU$8m
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$492k	AU$410k	-AU$15m
Mar 31 2023	n/a	n/a	-AU$15m
Dec 31 2022	n/a	n/a	-AU$15m
Sep 30 2022	n/a	n/a	-AU$17m
Jun 30 2022	AU$1m	AU$201k	-AU$19m

Compensatie versus markt: De totale vergoeding ($USD 328.17K ) Gisela } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 299.27K ).

Compensatie versus inkomsten: De vergoeding van Gisela is gestegen terwijl het bedrijf verliesgevend is.

CEO

Gisela Mautner

2.8yrs

Tenure

AU$500,623

Compensatie

Dr. Gisela Mautner is Non-Executive Director of Nyrada Inc. from August 1, 2022. She serves as Director at Noxopharm Limited. She served as Chief Medical Officer at Noxopharm Limited since October 2019 unt...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gisela Mautner	CEO, Executive MD & Director	2.8yrs	AU$500.62k	geen gegevens
Shawn Van Boheemen	Chief Financial Officer	5.6yrs	geen gegevens	geen gegevens
Jeanette Bell	Chief Operating Officer	4.8yrs	geen gegevens	geen gegevens
John Wilkinson	Chief Scientific Officer of Oncology	2.8yrs	geen gegevens	geen gegevens
Olivier Laczka	Chief Scientific Officer of Inflammation	2.8yrs	geen gegevens	geen gegevens
David Franks	Company Secretary	7.8yrs	AU$16.49k	geen gegevens

3.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van NOX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gisela Mautner	CEO, Executive MD & Director	no data	AU$500.62k	geen gegevens
Frederick Bart	Non-Executive Chairman	4.5yrs	AU$45.00k	2.57% A$ 1.0m
Peter Marks	Non-Executive Deputy Chairman	8.7yrs	AU$60.00k	0.31% A$ 121.5k
Boris Patkin	Non-Executive Director	4.7yrs	AU$45.00k	0.22% A$ 85.1k

4.7yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NOX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Noxopharm Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Noxopharm Limited, Annual General Meeting, Nov 19, 2024

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Non-Executive Chairman recently bought AU$50k worth of stock

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Recent updates

Noxopharm Limited, Annual General Meeting, Nov 19, 2024

New major risk - Market cap size

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Full year 2022 earnings released: AU$0.064 loss per share (vs AU$0.035 loss in FY 2021)

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

No independent directors

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Full year 2021 earnings released: AU$0.035 loss per share (vs AU$0.002 loss in FY 2020)

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

New 90-day high: AU$0.70

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Noxopharm Limited Provides Update on Its Ongoing New Immuno-Oncology Drug

Noxopharm Limited Announces Independent Discovery Validates Darrt Cancer Therapy

New 90-day high: AU$0.54

Noxopharm Limited Announce Partnership with Hudson Institute of Medical Research and Australian National University for the Formation of the New Australian Drug Development Company

New 90-day high: AU$0.44

Noxopharm Limited Announces the Final Patient Has Completes Treatment in the Lupin Study

Noxopharm Announces First COVID-19 Patient Treated in Veyonda Study

Noxopharm Limited Announces the Enrolment and Treatment of the First Patient into the Phase 1 NOXCOVID-1

New 90-day high: AU$0.39

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd